SecBot SecBot
PRESS-RELEASE ·Filed Mar 19, 2026

TSHA

Taysha Gene Therapies, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Investors should monitor upcoming Q2 2026 data readouts from the REVEAL Phase 1/2 trial and completion of dosing in pivotal trials, which could serve as key catalysts for BLA submission. The expanded cash runway into 2028 reduces near-term dilution risk.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.56
T+0 close · Mar 19, 2026 · via day close
Latest settled
+30.92%
T+60 · $5.97
Vs SPY
+16.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $4.56entry
  2. T+1 · 8mo ago −3.51%α −1.77% · $4.40
  3. T+5 · 8mo ago −5.26%α −3.05% · $4.32
  4. T+20 · 7mo ago +41.01%α +33.39% · $6.43
  5. T+60 · 5mo ago +30.92%α +16.58% · $5.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Taysha Gene Therapies reported financial results for 2025 and provided a corporate update highlighting progress in its TSHA-102 program for Rett syndrome, including dosing in pivotal trials, FDA alignment on BLA-enabling strategies, and a favorable safety profile. Revenue increased to $9.77 million, though net loss widened to $109.0 million due to higher R&D and administrative expenses. The company has $319.8 million in cash, sufficient to fund operations into 2028.

Key Financial Metrics

Revenue
$9.8M
+17.3% YoY
EPS
$-0.34

Key Facts

  • Revenue increased 17.3% YoY to $9.77 million in 2025
  • Net loss widened to $109.0 million in 2025 from $89.3 million in 2024
  • R&D expenses rose 30.9% to $86.4 million, driven by clinical trial and manufacturing costs
  • Cash and cash equivalents totaled $319.8 million as of December 31, 2025
  • FDA cleared initiation of ASPIRE trial and provided written alignment on CMC and BLA strategy
  • No treatment-related SAEs or DLTs observed in REVEAL trials as of March 2026
  • Dosing in REVEAL pivotal and ASPIRE trials on track for completion in Q2 2026

Financial Impact

Revenue grew 17.3% to $9.77 million, but net loss increased by $19.7 million due to higher R&D and G&A spending. Cash burn was significant, though offset by $50 million raised via ATM, leaving $319.8 million in cash.

revenuenet lossr_and_d_expensecash

Risk Factors

  • Clinical development risk: TSHA-102 remains investigational with no guarantee of regulatory approval
  • Cash burn remains high; future equity raises could lead to dilution despite current runway
  • Revenue is minimal and non-recurring (likely from collaborations), not indicative of commercial product sales

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258910

Track record

14 reports on TSHA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
  3. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
  4. Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
  5. Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
  6. Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
  7. Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
  8. May 6, 202627w ago 8-K Neutral 5/10 No price data
  9. May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
  10. Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026